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Abstract
Common phenotypes of cancer and stem cells suggest that breast
cancers arise from stem cells. Breast epithelial cells with stem cell
phenotypes have been shown to be more susceptible to
immortalization and neoplastic transformation. Breast tumor stem
cells with CD44+/CD24–/lowLineage¯ markers have been isolated.
The role of these cells in tumor progression and clinical outcome is
not clear. The relationship between breast stem cell and tumor
stem cell may be elucidated by further studies of carcinogenesis of
nonadherent mammosphere cells with stem cell features and by
derivation of CD44+/CD24–/low cells from an adherent breast
epithelial stem cell type.
Introduction
As summarized by Hanahan and Weinberg [1], cancer cells
possess several characteristics that may be considered
hallmarks of cancer. However, some major characteristics of
cancer cells were not included in that list, namely common
phenotypes of cancer and stem cells such as deficiency in
gap junctional intercellular communication (GJIC) [2] and
expression of genes that are involved in stem cell specific
function and self-renewal (e.g. Oct-4 [3] and other pathways
[4]). These common phenotypes suggest that cancers arose
from stem cells.
In human breast cancer, two lines of observations have been
cited as evidence in favor of the stem cell theory of carcino-
genesis. First, pregnancy may reduce the risk of breast
cancer possibly by inducing the differentiation of mammary
gland and reducing the number of breast stem cells [5].
Second, in a Japanese study of the effects of atomic bomb
detonation [6], evaluation of the radiation effect revealed that
young women were more susceptible to radiation-induced
breast cancer. Breast epithelial cells with stem cell features
have been isolated [7,8]. Characterization of these cells
provides more direct evidence for the stem cell hypothesis of
breast tumorigenesis. Recently, several different human
cancers, including breast cancer, were shown to contain
tumor-initiating stem cells [9-11]. These cells are believed to
sustain breast tumor growth and to be targets for cancer
treatment. However, the role of these cells in breast tumor
progression and the prevalence of these cells in clinical
outcome are not yet clear [12].
Common phenotypes of human breast
epithelial stem cells and tumor cells
Two types of normal human breast epithelial cells (HBECs)
derived from reduction mammoplasty have been isolated and
characterized [7]. Type I HBECs express estrogen receptor
(ER)-α and luminal epithelial cell markers (i.e. epithelial
membrane antigen and cytokeratin [CK]18). These cells also
exhibit stem cell characteristics, including deficiency in GJIC
[7], capacity for anchorage-independent growth (AIG) [13],
ability to differentiate into basal (type II HBECs) and luminal
(acini-forming) epithelial cells [7,13], expression of the
embryonic stem cell marker Oct-4 [3], and the ability to form
budding/ductal structures on Matrigel [13,14]. In contrast to
type II HBECs, which have basal epithelial characteristics
[7,13], type I HBECs share many common phenotypes with
breast carcinoma cells such as MCF-7, including deficiency
in GJIC and expression of ER-α, epithelial membrane antigen,
CK18, and Oct-4 [3,7,13-16].
Breast epithelial stem cells as major target
cells for carcinogenesis
Type I HBECs have been shown to be more susceptible to
telomerase activation and immortalization following SV40
(simian virus 40) large T-antigen transfection [14]. These
immortalized type I HBECs can then be converted to weakly
tumorigenic and highly tumorigenic cells by X-ray irradiation
(the best known breast carcinogen) and c-erbB2/neu (a well
known breast oncogene) [17]. Expression of Oct-4 [3] and
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lack of expression of the protease inhibitor maspin [16] were
identified in these cells at all stages of neoplastic transforma-
tion, providing strong evidence that type I HBECs are major
target cells for carcinogenesis. It should be noted that, in
contrast to type II HBECs, type I HBECs do not express
three genes (connexin 26, α6 integrin, and maspin) that are
considered to be tumor suppressor genes [18-20].
Furthermore, type I HBECs were capable of AIG at low and
high frequencies before and after overcoming senescence,
respectively [7,13]. In the literature many SV40 immortalized
HBECs have been reported, but none of them was capable
of AIG (for references, see the report by Kao and coworkers
[7]). Many of the tumor phenotypes possessed by type I
HBECs may contribute to the high susceptibility of these
cells to neoplastic transformation.
A different approach following the isolation of neuronal stem
cells as neurospheres [21] has been employed to isolate
nonadherent mammospheres [8]. These mammosphere cells
have been shown to differentiate along three mammary
epithelial lineages (luminal, myoepithelial, and alveolar) in
conditions that favor differentiation, and to clonally generate
complex functional structures in three dimensional culture.
The stem cell features of mammospheres also include
Hoechst dye exclusion and expression of some genes that
are involved in stem cell/progenitor cell-specific functions [4].
Unlike type I HBECs, mammosphere cells have not been
shown to express ER-α or Oct-4, and to be more susceptible
to neoplastic transformation.
Two breast tumor types phenotypically
corresponding to two normal HBEC types
Immunohistochemical and mRNA expression profiling studies
of large breast cancer cohorts have reproducibly identified a
subset (about 15%) of tumors expressing markers of the
basal layer of the mammary gland [22]. These tumors are
invariably ER negative with high p53 mutations, rarely contain
amplified HER2, and are generally high grade/poorly
differentiated and associated with poor prognosis. The
phenotypes of these cells are similar to those of type II
HBECs, which express basal epithelial cell markers and are
ER negative [7,13,15]. In contrast, the majority of human
breast cancers are ER positive, express luminal cytokeratins
(CK8, CK18, and CK19) and harbor a low frequency of p53
mutation [22]. The phenotypes of these tumors are clearly
similar to those of the type I HBECs, which express CK18,
CK19 and ER-α, and can be neoplastically transformed by
HER2/neu oncogene [13,17]. The corresponding pheno-
types of these two types of breast tumors with two types of
normal breast epithelial cells suggest two different target
cells for breast carcinogenesis, namely type I and early type II
HBECs, which are highly proliferative and could be pre-
cursors for myoepithelial cells. However, common mammary
stem or progenitor cells could give rise to two types of breast
tumors, as shown by the coexistence of luminal and
myoepithelial cells in mouse mammary tumors induced by
Wnt signaling [23] and the expression of different lineage-
specific markers by cultured breast tumor mammospheres
under differentiating conditions [24]. It is possible that tumor
stem cell differentiation may involve a wholesale switch in gene
expression, similar to the differentiation of type I HBECs [7].
The origin of breast tumor stem cells
In recent years cancer-initiating stem cells have been
reported for human leukemia, myeloma, and brain and breast
tumors. In most cases, the markers for cancer stem cells are
also markers for normal stem cells in the same tissue (i.e.
CD34+/CD38– for leukemia stem cells and hematopoietic
stem cells [25], and CD133+ and nestin+ for brain tumor
stem cells and normal neural stem cells [10]), suggesting that
the initiating target cells are stem cells and not the committed
progenitor cells. The breast cancer-initiating cells have been
identified as CD44+/CD24-/lowLineage¯ [11] and have not
been cultured as adherent cells. These markers were not
found in adherent type I HBEC with stem cell characteristics.
In fact, the immortal and tumorigenic type I HBECs were
CD44–/CD24+ [16]. The discrepancy could be due to the
selection of CD44+/CD24–/low cells, which are nonadherent,
and the culture of type I HBECs as adherent cells, which
would exclude CD44+/CD24– cells. Because a sub-
population of type I HBECs was capable of AIG [13], these
cells could exhibit a CD44+/CD24– phenotype and give rise
to the reported breast tumor stem cells.
In vitro propagation of tumor-initiating breast tumor cells has
recently been reported [24]. These cells are CD44+/
CD24–/low and Oct-4+/connexin 43–; the latter are similar to
type I HBECs [3,13]. On the other hand, although mammo-
spheres can be formed by a subpopulation of breast
epithelial cells and tumor cells. Some important breast tumor
phenotypes such as ER-α and Oct-4 expression and
deficiency in GJIC have not been demonstrated in normal
mammospheres. The origin of breast cancer from mammo-
sphere cells remains to be demonstrated. Identification and
elucidation of the nature of target cells for breast
carcinogenesis will help us to develop preventive, early
detection, and therapeutic strategies for breast cancer.
The role of CD44+/CD24–/low cells in tumor
progression and clinical outcome
The in vitro culture of CD44+/CD24– tumor mammospheres
was successful for a minority of breast tumor samples (three
out of 16) [24]. This indicates either the absence of
CD44+/CD24– in most breast tumors (13 out of 16) or a
limitation of the culture method. In a clinical study, the
CD44+/CD24–/low tumor cells were not found to increase in
tumor progression from carcinoma in situ to carcinoma but
may favor distant metastasis [12]. There was no significant
correlation between the prevalence of CD44+/CD24–/low
tumor cells and event-free or overall survival in breast cancer
patients. These findings must be verified by further
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Conclusion
There is substantial evidence in favor of the stem cell theory
of breast carcinogenesis, based on the observation of
phenotypes common to breast stem cells and tumor cells and
on the demonstration that breast epithelial cells with stem cell
features were more susceptible to neoplastic transformation.
However, the origin of breast tumor stem cells remains
unsettled. This may be resolved by identification of a
subpopulation of type I HBECs that are nonadherent and with
CD44+/CD24– expression and/or demonstration that the
nonadherent mammosphere cells are target cells for
neoplastic transformation. The reported lack of correlation
between the prevalence of CD44+/CD24– cells and clinical
outcomes requires examination in further studies.
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